Author: Customer Service

TORONTO, Nov. 07, 2025 (GLOBE NEWSWIRE) — Summit Royalties Ltd. (TSXV: SUM) (the “Corporation” or “Summit Royalties“) is pleased to announce corporate updates in connection with the recently completed go-public transaction by way of a reverse takeover (the “RTO“). Commencement of Trading on the TSX Venture Exchange In connection with the closing of the RTO and further to its news release on November 5, 2025 (titled “Summit Royalties Completes Go-Public Transaction”), the common shares of the Corporation (the “Common Shares“) are scheduled to commence trading on the TSX Venture Exchange (the “Exchange“) at market open on Monday, November 10, 2025, under the symbol “SUM”. In anticipation of commencement of trading on the Exchange, the Common Shares...

New biomarker and immune data presented at the Society for Immunotherapy of Cancer (SITC) 2025 Annual Meeting Following the recent presentation of unprecedented two-year clinical efficacy data from the phase 2 trial, the new data further adds to EVX-01’s already strong data packageCOPENHAGEN, Denmark, November 7, 2025 – Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, announces new data exploring immune responses following treatment with AI-designed personalized cancer vaccine EVX-01. The data was presented today in a poster session at the Society for Immunotherapy of Cancer (SITC) 2025 Annual Meeting taking place in National Harbor, Maryland. Developed with Evaxion’s AI-Immunology™ platform, EVX-01 is designed to target multiple...

VANCOUVER, British Columbia, Nov. 07, 2025 (GLOBE NEWSWIRE) — Maxus Mining Inc. (“Maxus” or the “Company”) (CSE: MAXM | FRA: R7V), is pleased to announce the closing of its non-brokered private placement, announced October 29, 2025, for an aggregate of 2,364,091 flow-through shares of the Company (each, a “FT Share”) at a price of C$1.10 per FT Share for gross proceeds of C$2,600,500.10 (the “Offering”). The Company intends to use the proceeds from the Offering towards exploration on the Company’s project portfolio. Each FT Share consists of one (1) common share of the Company issued as a “flow-through share” within the meaning of the Income Tax Act (Canada). The gross proceeds from the sale of the FT Shares will be used by the Company to incur eligible “Canadian exploration expenses” that will qualify as “flow-through mining expenditures”...

Oral presentation of biomarker data shows RP1 plus nivolumab reverses multiple resistance mechanisms to PD-1 blockade in advanced melanoma following definitive anti-PD-1 failure WOBURN, Mass., Nov. 07, 2025 (GLOBE NEWSWIRE) — Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today announced that biomarker data and updated clinical data from the IGNYTE clinical trial of RP1 plus nivolumab was presented as a late-breaking abstract during an oral session at the 40th Annual Meeting of the Society for the Immunotherapy of Cancer (SITC 2025) in National Harbor, Maryland. Two additional posters on RP1 are also being presented. “These data are important because they demonstrate that RP1 plus nivolumab can potentially reprogram the tumor microenvironment...